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Abstract: Progressive inflammation and anemia are common in tuberculosis (TB) and linked
to poor clinical outcomes. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have
inflammation-resolving properties, whereas iron supplementation in TB may have limited efficacy
and enhance bacterial growth. We investigated effects of iron and EPA/DHA supplementation,
alone and in combination, on inflammation, anemia, iron status markers and clinical outcomes
in Mycobacterium tuberculosis-infected C3HeB/FeJ mice. One week post-infection, mice received
the AIN-93 diet without (control) or with supplemental iron (Fe), EPA/DHA, or Fe+EPA/DHA for
3 weeks. Mice supplemented with Fe or EPA/DHA had lower soluble transferrin receptor, ferritin and
hepcidin than controls, but these effects were attenuated in Fe+EPA/DHA mice. EPA/DHA increased
inflammation-resolving lipid mediators and lowered lung IL-1α, IFN-γ, plasma IL-1β, and TNF-α.
Fe lowered lung IL-1α, IL-1β, plasma IL-1β, TNF-α, and IL-6. However, the cytokine-lowering effects
in the lungs were attenuated with Fe+EPA/DHA. Mice supplemented with EPA/DHA had lower lung
bacterial loads than controls, but this effect was attenuated in Fe+EPA/DHA mice. Thus, individually,
post-infection EPA/DHA and iron supplementation lowered systemic and lung inflammation and
mitigated anemia of infection in TB, but not when combined. EPA/DHA also enhanced bactericidal
effects and could support inflammation resolution and management of anemia.
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1. Introduction
Anemia is a common complication in tuberculosis (TB), affecting 30–94% of diagnosed TB
patients [1–6]. In addition, anemia has been linked to poor TB outcomes, such as delayed sputum
conversion, higher mortality rates and TB reoccurrence [3,7–9]. Exaggerated progressive inflammation
is characteristic of TB, and induces hepatic hepcidin synthesis [2,10]. Hepcidin is the main regulator of
iron homeostasis and mediates the degradation and internalization of the iron exporter ferroportin in
macrophages, hepatocytes, and enterocytes [11]. This leads to intracellular sequestration of iron and the
inhibition of iron absorption [12,13]. Consequently, hepcidin limits iron availability for pathogens that
rely on host iron stores [14,15]. The persistent inflammation in TB patients also restricts iron availability
for erythropoiesis and results in anemia of infection [6,16]. Anemia of inflammation (which includes
anemia of infection) and iron-deficiency anemia are the two most common anemias worldwide and
often co-exist [17,18]. Although less common in TB, iron-deficiency anemia resulting from low dietary
iron intake, amongst other causes, also affects TB patients and may contribute to disease susceptibility
and progression [1–3,19]. Iron supplementation may be essential for those patients with iron-deficiency
anemia [1–3,19,20]. However, the treatment of anemia with iron is complicated by impaired absorption
and the risk of promoting bacterial growth and inflammation, resulting in poor clinical outcomes [6,14].
Omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) have anti-inflammatory and
pro-resolving properties, and our group and others have demonstrated that these fatty acids (FAs)
lower the excessive inflammation in TB [21,22]. Omega-3 LCPUFAs serve as precursors for lipid
mediator (LM) synthesis, including the inflammation-resolving protectins, resolvins, and maresins that
are metabolized from docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) [23]. Therefore,
we hypothesized that n-3 LCPUFA administration would result in a shift towards a more pro-resolving
LM profile and a reduction in inflammation, which might lower the burden of anemia of infection in
TB patients.
In addition, our group has previously shown that iron supplementation resulted in a
pro-inflammatory LM profile and increased respiratory morbidity in iron-deficient South African (SA)
school-children [24,25]. However, in children supplemented with a combination of iron and EPA
plus DHA a pro-resolving LM profile was maintained, and the iron-induced increase in respiratory
morbidity was attenuated [24,25]. We, therefore, hypothesized that providing a combination treatment
of iron and n-3 LCPUFAs might potentially be an approach to deliver iron more safely in TB. Thus,
this study aimed to investigate the effect of iron and EPA plus DHA supplementation, alone and
in combination, on inflammation, anemia and iron status markers, as well as bacterial burden, in
Mycobacterium tuberculosis (Mtb)-infected C3HeB/FeJ mice.
2. Materials and Methods
2.1. Animals and Ethics Statement
Male C3HeB/FeJ mice (Jackson Laboratory, Bar Harbour, ME, USA), aged 10 to 12 weeks, were
bred and housed at the Institute of Infectious Diseases and Molecular Medicine (IDM), University
of Cape Town (UCT), Cape Town, SA. Following infection, mice were housed in a biosafety level 3
containment facility, five per individually ventilated cage with filter tops (type 2 long), as well as dried
wood shavings and shredded filter paper as floor coverings. The temperature range was set at 22–24 ◦C
and 12 h–12 h light cycles. The experiments were performed following SA National Guidelines and
UCT practice guidelines for laboratory animal procedures. The protocol was approved by the Animal
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Ethics Committee, Faculty of Health Sciences, UCT (AEC 015/040) and the AnimCare Animal Research
Ethics Committee of the North-West University (NWU-00260-16-A5).
2.2. Experimental Design and Animal Diets
Figure 1 provides an overview of the experimental design. Mice had ad libitum access to food
and water and were conditioned on the same standardized AIN-93G purified rodent diet for six weeks
before infection. Baseline hemoglobin (Hb) concentrations in all mice, and the total phospholipid FA
composition of red blood cells (RBCs) in a sub-sample of mice (n = 6), were measured in tail vein blood
before infection. Mice were then infected with Mtb via the aerosol route (described below). One week
post-infection, the mice were randomly allocated to continue on the AIN-93G control diet (control,
n = 10); to receive the AIN-93G control diet supplemented with EPA and DHA (EPA/DHA, n = 10); the
AIN-93G control diet supplemented with iron (Fe, n = 10); or the AIN-93G control diet supplemented
with iron and EPA plus DHA (Fe+EPA/DHA) (n = 10). The mice were fed these diets for three weeks,
whereafter they were euthanized at 28 days post-infection. An uninfected reference group was kept on
the same AIN-93G control diet throughout the study period (n = 3). All the purified experimental
diets were obtained commercially (Dyets, Bethlehem, PA, USA), and were based on the AIN-93G
formulation [26], all containing 10% fat, but with modifications in fat source and/or iron content. The
dietary FA and iron composition of the experimental diets are presented in Table 1. All the diets were
isocaloric with the same macronutrient content. The EPA/DHA supplemented diets (EPA/DHA and
Fe+EPA/DHA) contained commercially obtained Incromega TG4030 oil (Croda Chemicals Europe,
Goole, East Yorkshire, UK) with a minimum EPA at 44% of total FAs and DHA at 28% of total FAs. Gas
chromatography-mass spectrometry (GCMS) analysis was performed by the manufacturer to confirm
the FA and iron composition of the diets (Table 1). The daily food intake per mouse was calculated by
dividing the weekly food intake by seven (days) and then by five (five mice per cage). Bodyweight
and food intake of mice were measured weekly. The results of this experiment were reproduced in a
second experiment (resulting in ten mice per treatment group). The data of one experiment (five mice
per group) are presented in this article.
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Figure 1. Experimental study design. EPA/DHA: eicosapentaenoic and docosahexaenoic acid 
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Table 1. Iron content, fat source, and fatty acid composition of the experimental diets 1.
Group Iron Fat Source LA ALA AA DHA EPA
Per 100 g diet
Control and
uninfected 40 ppm
7 g soybean oil
3 g Coconut oil 3.54 g 0.44 g <0.01 g <0.01 g <0.01 g
Fe 130 ppm 7 g Soybean oil3 g Coconut oil 3.48 g 0.44 g <0.01 g <0.01 <0.01 g
EPA/DHA 40 ppm
7 g Soybean oil
2.7 g Coconut oil
3 g Incromega TG4030 oil
1.3 g 0.43 g <0.01 g 0.06 g 0.09 g
Fe+EPA/DHA 123 ppm
7 g Soybean oil
2.7 g Coconut oil
3 g Incromega TG4030 oil
3.44 g 0.43 g <0.01 g 0.06 g 0.09 g
1 Based on gas chromatography-mass spectrometry (GCMS) analysis of diets. AA: arachidonic acid; ALA:
alpha-linolenic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; EPA/DHA: eicosapentaenoic and
docosahexaenoic acid supplemented group; Fe: iron supplemented group; Fe+EPA/DHA: iron and eicosapentaenoic
and docosahexaenoic acid supplemented group; LA: linoleic acid.
2.3. Aerosol Infection
A virulent Mtb H37Rv strain was cultured and stocks were prepared and stored at −80 ◦C, as
described elsewhere [27]. Mice were exposed to aerosol infection for 40 min by nebulizing 6 mL of
a suspension that contained 2.4 × 107 live bacteria in an inhalation exposure system (model A4224,
Glas-Col). One day following infection, four mice were euthanized to confirm the infection dose, which
was 500 colony-forming units (CFU)/mouse.
2.4. Endpoint Blood and Tissue Collection
After three weeks of receiving intervention diets, mice were euthanized by halothane
exposure, followed by blood collection via heart puncture. The blood was collected into
ethylenediaminetetraacetic acid (EDTA) coated Microtainer® tubes (K2EDTA, 1000 µL, BD), Hb
measured in whole blood and then centrifuged at 8000 rpm. The plasma was removed for ferritin,
soluble transferrin receptor (sTfR), hepcidin and cytokine analyses and buffy coat for FA analysis. The
RBCs were washed twice with saline before storage at −80 ◦C and subsequent FA analysis. The liver
and lung lobes were removed aseptically and weighed before preparation. The left lung lobe was
homogenized in saline and 0.04% Tween-80 for the analysis of the bacillary load and lung cytokines.
The right superior and post-caval lung lobes and the liver were snap-frozen in liquid nitrogen and
stored at −80 ◦C for lung FA, LM and liver iron analyses. The right middle lobe was submerged
in 10% neutral buffered formalin for histological analysis and the right inferior lobe prepared for
flow cytometry.
2.5. Total Phospholipid FA Composition Analysis
FAs were extracted from ~20 mg lung tissue, homogenized in 10 µL phosphate-buffered saline
with protease inhibitor (homogenization buffer) per 1 mg tissue, or from ~200 µL RBCs or peripheral
blood mononuclear cells (PBMCs) collected as buffy coat. Lipids were extracted from each lipid pool
with chloroform: methanol (2:1, v:v; containing 0.01% butylated hydroxytoluene) by a modification of
the method of Folch et al. [28]. The lipid extracts were concentrated and the neutral lipids separated
from the phospholipids by thin-layer chromatography (TLC) (silica gel 60 plates, Merck) and eluted
with diethyl ether: petroleum ether: acetic acid (30:90:1, v:v:v). The lipid band containing phospholipids
was removed from the TLC plate and transmethylated with methanol: sulfuric acid (95:5, v:v) at 70 ◦C
for 2 h to form fatty acid methyl esters (FAME). FAMEs were analyzed with an Agilent Technologies
7890A gas chromatography system equipped with an Agilent Technologies 7000B triple quad mass
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selective detector (Agilent Technologies, Santa Clara, CA, USA) and quantification performed with
Masshunter (B.06.00). Relative percentages of FAs (% w/w) were calculated by taking the concentration
of a given FA as a percentage of the total concentration of all FAs identified in the sample.
2.6. Lipid Mediator Analysis
LMs in crude lung homogenates were analyzed with liquid chromatography-tandem mass
spectrometry. Seventeen-hydroxy-docosahexaenoic acid (17-HDHA); 5-, 11-, 12-, 15- and
18-hydroxy-eicosapentaenoic acid (HEPE); 5-, 8-, 9-, 11-, 12-, and 15-hydroxy-eicosatetraenoic acid
(HETE); prostaglandin D1 (PGD1); PGE2; PGE3 and PGD2 concentrations were measured. LMs were
extracted from ~50 mg lung tissue, in 10 µL/mg homogenization buffer, with solid-phase extraction
using Strata-X (Phenomenex, Torrance, CA, USA). The method was modified for Strata-XSPE columns
from a previously described method [25]. Data were quantified with Masshunter B0502, using external
calibration for each compound and internal standards (PGD2-d4, PGE2-d4, PGF2-d4 and 5- and
12-HETE-d8; 1000 pg of each (Cayman Chemicals, Ann Arbor, MI, USA)) to correct for losses and
matrix effects.
2.7. Cytokine Analysis
The cytokines interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17,
monocyte chemoattractant protein 1 (MCP-1), interferon-gamma (IFN-γ), tumor necrosis factor-alpha
(TNF-α), chemokine ligand 3 (CCL3), granulocyte-macrophage colony-stimulating factor (GMCSF),
and chemokine ligand 5 (CCL5) were measured in cell-free lung homogenates and plasma. Cytokines
were analyzed using the Quansys Biosciences Q-Plex™ Mouse Cytokine Screen (West Logan, WV,
USA) 16-plex array for mouse cytokines according to manufacturer instructions. Arrays were analyzed
using the Q-View Imager Pro and Q-View Software.
2.8. Markers of Iron Status and Anemia of Infection
Hb concentrations were measured before infection in tail vein whole blood and directly after
euthanasia blood collection in whole blood using a portable HemoCue® Hb 201+ photometer
(HemoCue AB, Angelholm, Sweden). Mice-specific enzyme-linked immunosorbent assays (ELISA)
kits from ELAB Science (Houston, TX, USA) were used for the analysis of ferritin, sTfR and hepcidin
concentrations in plasma. Liver iron analysis was performed on an Agilent 7900 quadrupole ICP-MS
instrument in He collision mode MS at the Central Analytical Facilities, Stellenbosch University, SA.
The instrument was calibrated with National Institute of Standards and Technology (NIST) traceable
standards, and the accuracy of the method for iron in blood verified using the certified reference
material Seronorm L2, prepared in the same way as the samples.
2.9. Lung Histopathology Analysis
Right middle lobes of the lungs were dissected out and fixed in 10% neutral buffered formalin. The
tissue was processed using the Leica TP 1020 Processor for 24 h and subsequently embedded in paraffin
wax. The Leica Sliding Microtome 2000R was used to cut 2 µm-thick sections of the embedded tissues.
Three sections with 30 µm distance apart per section were cut, deparaffinized, and subsequently
stained with the hematoxylin/eosin stain. The images were acquired in Nikon Eclipse 90i microscopes
and analyzed with NIS-Elements AR software (Nikon Corporation, Tokyo, Japan) to determine the
granulomatous area and alveolar space as a percentage of the total lung tissue [29].
2.10. Flow Cytometry
Single-cell suspensions of the lung tissues were prepared by cutting them into small pieces followed
by incubation in Dulbecco’s Modified Eagle Media (DMEM) containing 0.18 mg/mL Collagenase Type I
(Sigma, St. Louis, MO, USA), 0.02 mg/mL DNase I (Sigma, St. Louis, MO, USA) for 1 h at 37 ◦C under
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constant rotation, followed by being mechanically passed through a 100 µm and 70 µm cell strainer
sequentially. Erythrocytes were lysed using RBC lysis buffer (155 mM NH4Cl, 12 mM NaHCO3,
0.1 mM EDTA). Cells were then counted and subjected to flow cytometry. Lymphoid and myeloid
compartments were investigated in the lung samples of mice on various intervention diets. Antibodies
used for flow cytometry analysis were as follows: CD64-PeCy7 (Clone X54-5/7.1), Ly6C-PerCPCy5.5
(Clone AL-21), CD11b-V450 (Clone M1/70), MHCII-APC (Clone M5/114.15.2), CD103-PE (Clone M290),
CD11c-A700 (Clone HL3), SiglecF-APCCy7 (Clone E5-2440), Ly6G-FITC (Clone 1A8), PD-1-FITC
(Clone 29F.1A12), CD4-BV510 (Clone RM4-5), CD44-PE (Clone IM7), NK1.1-APCCy7 (Clone PK136),
CD3-A700 (Clone 500A2), CD62L-V450 (Clone MEL-14), CD19-PerCPCy5.5 (Clone 1D3), CD8-APC
(Clone 53-6.7), and KLRG1-BV786 (Clone 2F1) purchased from BD (Biosciences, Johannesburg, SA)
and eBioscience (ThermoFisher, Johannesburg, SA) [29,30].
2.11. Bacterial Load Determination
The bacterial loads of lungs were determined at euthanasia (28 days after infection). The left
lung of each mouse was aseptically removed, weighed, homogenized and serial dilutions were
plated onto DifcoTM Middlebrook 7H10 Agar (BD Biosciences, Johannesburg, SA) medium with
oleic acid-albumin-dextrose-catalase (OADC) supplementation and 0.5% glycerol. The CFU were
determined 21 days following incubation at 37 ◦C. Data are expressed as log10 CFU.
2.12. Statistical Analyses
Using the G*Power statistical package version 3.1.9.3, a Student’s t-test power analysis was done
to identify significant differences in the concentrations of lung IFN-γ and bacterial load. A sample size
of n = 4 was calculated for a two-sided alpha of 0.05 and a power of 80%. Effect sizes were estimated
using the results of a preliminary study (unpublished results). Data are presented as mean ± standard
error of the mean (SEM). Statistical analyses were performed using IBM SPSS statistics software
(version 25; IBM Corporation). The main effects of EPA/DHA (EPA/DHA & Fe+EPA/DHA versus
control & Fe) and iron (Fe & Fe+EPA/DHA versus EPA/DHA & control) supplementation, and their
interaction (Fe × EPA/DHA), on all outcome variables, were analyzed by using two-way factor analysis
of variance (ANOVA). Significant treatment effects in the absence of a significant interaction effect
indicate additive effects of the treatments, whereas a significant interaction implies synergism or
antagonism. In the presence of a significant main effect or interaction, between-group differences were
examined using one-way ANOVA and the Tukey post-hoc test. For Hb, ferritin, sTfR, and hepcidin
parameters, Fisher’s least significant difference post-hoc test was used. Data for ferritin and hepcidin
concentrations were log-transformed before statistical analyses to improve normality. The differences
in indices of iron status and anemia of infection between the infected intervention groups and the
uninfected reference group were determined by the Dunnett two-sided t-test. A p-value of less than
0.05 was considered significant.
3. Results
3.1. Food Intake and Body Weight Gain
The food intake and percentage body weight gain of mice were measured weekly during
the four-week infection period. There was no difference in food intake between groups (control,
3.41 ± 0.18 g; Fe, 3.38 ± 0.18 g; EPA/DHA, 3.18 ± 0.15 g; Fe+EPA/DHA, 3.36 ± 0.14 g). However,
iron supplementation lowered the percentage of body weight gain in Mtb-infected mice (p < 0.001).
The control (6.70 ± 0.63%) and EPA/DHA (8.12 ± 1.19%) groups had a significantly higher percentage
weight gain compared with the groups supplemented with iron (Fe, 0.88 ± 1.50% and Fe+EPA/DHA,
0.16 ± 1.50%) (control vs. Fe, p < 0.001; control vs. Fe+EPA/DHA, p = 0.001; EPA/DHA vs. Fe, p = 0.002;
and EPA/DHA vs. Fe+EPA/DHA, p = 0.005).
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3.2. Total Phospholipid FA Composition of RBCs, PBMCs, and Crude Lung Homogenates
Table 2 presents the phospholipid FA composition of RBCs, PBMCs, and crude lung homogenates
of all infected groups, measured at the endpoint (four weeks post-infection). From Table 2 it is evident
that EPA/DHA supplementation resulted in higher phospholipid EPA, DHA, and total n-3 LCPUFAs
(all p < 0.001). On the other hand, iron supplementation lowered EPA (p = 0.041 and p = 0.038) and
total n-3 LCPUFAs (p = 0.046 and p = 0.011) in RBCs and PBMCs, as well as DHA in PBMCs (p = 0.008).
With regards to n-6 PUFAs, EPA/DHA supplementation lowered arachidonic acid (AA), osbond acid,
total n-6 LCPUFAs and total n-6/n-3 LCPUFA ratios in RBCs, PBMCs and crude lung homogenates
(all p < 0.001, except for AA in PBMCs p = 0.001, AA in lungs p = 0.023 and total n-6 LCPUFAs in
PBMCs p = 0.001). Iron also lowered osbond acid in RBCs and PBMCs (p = 0.008 and p = 0.025).
Additionally, there were Fe × EPA/DHA interactions in RBCs and PBMCs (p < 0.021 and p = 0.005)
to lower osbond acid. There was an effect of iron supplementation for higher AA (p < 0.001 and
p = 0.013) and total n-6 LCPUFAs (p = 0.001 and p = 0.022) in PBMCs and lung homogenates, and
n-6/n-3 LCPUFA ratios in RBCs, PBMCs and lung homogenates (p = 0.004, p < 0.001 and p = 0.039).
Respective differences between groups are shown in Table 2.
Table 2. Phospholipid FA composition of RBCs, PBMCs, and crude lung homogenates in Mtb-infected
mice receiving control, EPA/DHA, Fe, or Fe+EPA/DHA diets for three weeks 1.
% Total FA Control EPA/DHA Fe Fe+EPA/DHA
p-Value 2
EPA/DHA Fe Fe × EPA/DHA
20:5(n-3) (EPA)
RBC 0.13 ± 0.00 b 0.51 ± 0.04 a 0.12 ± 0.00 b 0.43 ± 0.02 a <0.001 0.041 0.17
PBMC 0.20 ± 0.01 b 0.89 ± 0.04 a 0.16 ± 0.01 b 0.55 ± 0.11 a <0.001 0.038 0.19
Lung 0.17 ± 0.01 b 0.40 ± 0.01 a 0.17 ± 0.03 b 0.38 ± 0.01 a <0.001 0.74 0.63
22:6(n-3) (DHA)
RBC 6.09 ± 0.21 b,c 7.48 ± 0.41 a 5.58 ± 0.22 c 6.83 ± 0.25 a,b <0.001 0.060 0.82
PBMC 9.04 ± 0.20 a 9.82 ± 0.22 a 7.57 ± 0.29 b 9.52 ± 0.39 a <0.001 0.008 0.060
Lung 8.08 ± 0.15 b 9.68 ± 0.28 a 7.99 ± 0.08 b 9.86 ± 0.13 a <0.001 0.75 0.38
Total n-3 LCPUFAs
RBC 6.63 ± 0.20 b,c 8.59 ± 0.48 a 6.06 ± 0.24 c 7.80 ± 0.27 a,b <0.001 0.046 0.74
PBMC 10.60 ± 0.21 b 12.40 ± 0.33 a 8.76 ± 0.42 c 11.80 ± 0.64 a,b <0.001 0.011 0.20
Lung 10.00 ± 0.14 b 12.60 ± 0.26 a 9.73 ± 0.10 b 12.90 ± 0.12 a <0.001 0.96 0.07
20:4(n-6) AA
RBC 17.71 ± 0.27 a 16.42 ± 0.30 a,b 17.68 ± 0.40 a 15.88 ± 0.28 b <0.001 0.38 0.43
PBMC 16.36 ± 0.39 b 14.76 ± 0.31 b 20.94 ± 0.70 a 17.34 ± 0.94 b 0.001 <0.001 0.14
Lung 14.40 ± 0.15 a,b 13.32 ± 0.42 b 14.76 ± 0.27 a 14.31 ± 0.23 a,b 0.023 0.013 0.25
22:5(n-6) (osbond)
RBC 0.87 ± 0.10 a 0.37 ± 0.01 c 0.49 ± 0.01 b 0.35 ± 0.00 c <0.001 0.008 0.021
PBMC 1.42 ± 0.04 a 0.74 ± 0.05 b 1.01 ± 0.08 b 0.80 ± 0.10 b <0.001 0.025 0.005
Lung 1.13 ± 0.05 a 0.54 ± 0.01 b 1.01 ± 0.02 a 0.54 ± 0.01 b <0.001 0.27 0.050
Total n-6 LCPUFAs
RBC 20.20 ± 0.32 a 18.7 ± 0.44 a 20.10 ± 0.47 a,b 18.00 ± 0.33 b <0.001 0.33 0.45
PBMC 21.80 ± 0.41 b 19.4 ± 0.54 b 25.70 ± 0.78 a 22.00 ± 1.16 b 0.001 <0.001 0.45
Lung 21.20 ± 0.19 a,b 18.3 ± 0.50 c 21.50 ± 0.37 a 19.90 ± 0.35 b <0.001 0.022 0.07
Total n-6/n-3 LCPUFA ratio
RBC 3.05 ± 0.05 b 2.19 ± 0.07 c, 3.32 ± 0.07 a 2.31 ± 0.04 c <0.001 0.004 0.19
PBMC 2.06 ± 0.02 b 1.55 ±0.01 b 2.94 ± 0.14 a 1.91 ± 0.23 b <0.001 <0.001 0.07
Lung 2.12 ± 0.19 a 1.45 ± 0.50 b 2.21 ± 0.03 a 1.54 ± 0.04 b <0.001 0.039 0.97
1 Values are presented as mean ± SEM. Results repeated in two experiments, data shown for one experiment
(n = 5 per group, except for Fe group PBMCs n = 4 and Fe+EPA/DHA group lungs n = 4). 2 A two-way ANOVA
was used to test effects of EPA/DHA (control & Fe vs. EPA/DHA & Fe+EPA/DHA), Fe (control & EPA/DHA vs.
Fe & Fe+EPA/DHA), and Fe × EPA/DHA interactions. One-way ANOVA followed by Tukey post-hoc test was
used to compare groups. Means in a row without common superscript letters differ significantly, p < 0.05. AA:
arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; EPA/DHA: eicosapentaenoic acid and
docosahexaenoic acid-supplemented group; FA: fatty acid; Fe: iron-supplemented group; Fe+EPA/DHA: iron plus
eicosapentaenoic acid and docosahexaenoic acid-supplemented group; LCPUFA: long-chain polyunsaturated fatty
acid; lung: crude lung homogenates; PBMC: peripheral blood mononuclear cells; RBC: red blood cell.
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3.3. Biomarkers of Iron Status and Anemia of Infection
We further evaluated indices of iron status as well as hepcidin concentrations to determine the
effects of the intervention diets on biomarkers that have been linked to hypoferremia and anemia
in TB. We observed a significant effect of EPA/DHA supplementation for lower Hb concentrations
(p = 0.031), and a trend for an Fe × EPA/DHA interaction (p = 0.08) (Table 3). The Hb concentrations in
the EPA/DHA supplemented mice did not differ from the control group but were significantly lower in
the Fe+EPA/DHA (p = 0.009) compared with the Fe supplemented mice (Table 3). However, when
compared with a non-infected reference group fed the control diet (n = 3), Mtb-infection did not result
in lower Hb concentrations in control mice nor in the mice supplemented with Fe and/or EPA/DHA.
Table 3. Biomarkers of iron status and anemia of infection in Mtb-infected mice receiving control,

















EPA/DHA Fe Fe ×EPA/DHA
Hb
(g/dL) 14.4 ± 0.8 13.6 ± 0.3
a,b 13.4 ± 0.3 a,b 14.3 ± 0.4 a 12.9 ± 0.4 b 0.031 0.59 0.08
Liver iron
(µg/L) 288.0 ± 14.0 210.8 ± 12.7
b,c * 225.0 ± 16.7 b 299.4 ± 15.9 a 255.8 ± 18.4 a,b,c 0.38 0.002 0.09
Ferritin
(ng/mL) 26.1 ± 2.5 222.0 ± 43.9
a ** 136.0 ± 32.5 a,b 125.0 ± 23.4 b 164.0 ± 13.8 a,b * 0.51 0.63 0.045
sTfR
(ng/mL) 2.3 ± 0.1 17.5 ± 2.8
a ** 10.8 ± 2.4 b 10.8 ± 2.2 b 14.5 ± 0.9 a,b ** 0.49 0.50 0.030
Hepcidin
(µg/mL) 0.9 ± 1.1 14.3 ± 2.7
a ** 8.1 ± 2.2 b 8.7 ± 2.1 a,b 10.1 ± 4.6 a,b ** 0.71 0.36 0.044
1 Values are means ± SEM. Results repeated in two experiments, data shown for one experiment (n = 5 per group).
2 Different from the uninfected reference group determined by Dunnett’s two-sided t-test. * p < 0.05, ** p < 0.01.
3 Two-way ANOVA was used to test the effects of EPA/DHA (control & Fe vs. EPA/DHA & Fe+EPA/DHA), Fe (control
& EPA/DHA vs. Fe & Fe+EPA/DHA), and Fe×EPA/DHA interactions. One-way ANOVA followed by Tukey post-hoc
test was used to compare groups. Means in a row without common superscript letters differ significantly, p < 0.05.
EPA/DHA: eicosapentaenoic acid and docosahexaenoic acid supplemented-group; Fe: iron supplemented-group;
Fe+EPA/DHA: iron plus eicosapentaenoic acid and docosahexaenoic acid supplemented-group; Hb: hemoglobin;
sTfR: soluble transferrin receptor.
On the other hand, liver iron concentrations were significantly lowered by Mtb-infection in the
control group compared with the healthy reference group (p = 0.048). There was a significant effect of
iron supplementation in increasing liver iron concentrations (p = 0.002) and a tendency towards an
antagonistic interaction between Fe × EPA/DHA (p = 0.090). The Fe group had significantly higher
liver iron concentrations compared with the control (p = 0.006) and EPA/DHA (p = 0.023) groups, but
this effect tended to be attenuated with combined Fe+EPA/DHA supplementation (Table 3).
Mtb-infection significantly increased sTfR, ferritin and hepcidin concentrations in the control group
compared with a non-infected reference group (p = 0.002, p = 0.001, and p = 0.002) (Table 3). We found
antagonistic Fe × EPA/DHA interactions on sTfR (p = 0.030), ferritin (p = 0.045) and hepcidin (p = 0.044)
concentrations. The mice receiving the diets supplemented with EPA/DHA or Fe alone presented with
significantly lower sTfR concentrations compared with the control group (both p = 0.045), but this sTfR
lowering effect of EPA/DHA and iron alone was attenuated in mice supplemented with Fe+EPA/DHA
(Table 3). Similarly, the mice supplemented with Fe alone had significantly lower ferritin concentrations
(p = 0.040) and the mice supplemented with EPA/DHA tended (p = 0.06) to have lower concentrations
than the control mice. The ferritin concentrations of the combined Fe+EPA/DHA group did not
differ from any of the other groups. Additionally, the mice supplemented with EPA/DHA presented
with significantly lower (p = 0.047) and the mice supplemented with iron tended to have lower
(p = 0.07) hepcidin concentrations compared with the control group, with the Fe+EPA/DHA group not
having significantly different hepcidin concentrations from the other groups. When compared with
the non-infected reference group, sTfR, ferritin and hepcidin concentrations remained significantly
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higher in the Fe+EPA/DHA group (p = 0.027, p = 0.007, p = 0.029) but did not differ from the mice
supplemented with EPA/DHA or Fe alone.
3.4. Tuberculosis Related Clinical Outcomes
Figure 2 shows the lung- and spleen-weight-indexes amongst the different groups. This represents
the weight of either the lungs or spleen in relation to the bodyweight of the mice (spleen or lung
weight divided by endpoint bodyweight). A higher index represents worse disease severity. There
were antagonistic Fe × EPA/DHA interactions on lung- and spleen-weight indexes (p = 0.009 and
p = 0.002) in Mtb-infected mice (Figure 2). The mice supplemented with Fe alone tended to have a
lower lung-weight-index when compared with the control mice (p = 0.08), but this lung-weight-index
lowering trend of iron supplementation was attenuated in the mice supplemented with Fe+EPA/DHA
(Fe+EPA/DHA vs. control, p = 0.99) (Figure 2a). In contrast, only the mice supplemented with
EPA/DHA presented with a lower spleen-weight-index compared with the control group (p = 0.012),
but this decrease was attenuated in the mice supplemented with Fe+EPA/DHA (Fe+DHA/EPA vs.
control, p = 0.99) (Figure 2b).
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Mean (a) lung-weight-index and (b) spleen-weight-index after providing Mtb-infected
m ce with control, EPA/DHA, Fe, or Fe+EPA/DHA diets for three weeks. Results repeated in two
i t ( 5 per group). Two-way ANOVA was used to test
ff t / ( EP / ), Fe (control & EP / vs. Fe &
EP / i t r ctions. One-way ANOVA fo lowed by Tukey post-hoc test
s t s. 0.05, ** p < 0.01. EPA/DHA: eicosapentaenoic and docosahexaenoic
acid supplemented-group; Fe: iron-supplemented group; Fe+EPA/DHA: iron plus eicosapentaenoic
and docosahexaenoic acid-supplemented group.
Figure 3 shows the lung bacterial loads, percentage of free alveolar space and lung histology
images, which represent the disease severity and lung pathology of the various groups. We found
a significant antagonistic Fe × EPA/DHA interaction on lung bacterial load (p = 0.009) (Figure 3a)
and a trend for an interaction on free alveolar space (%) (p = 0.08) (Figure 3b). Supplementation of
EPA/DHA alone lowered lung bacterial load compared with the control mice (p = 0.008), but this effect
was attenuated in the mice supplemented with EPA/DHA and Fe in combination (Fe+EPA/DHA vs.
control, p = 0.69).
Nutrients 2020, 12, 2897 10 of 21
Nutrients 2020, 12, x FOR PEER REVIEW 10 of 22 
 
acid supplemented-group; Fe: iron-supplemented group; Fe+EPA/DHA: iron plus eicosapentaenoic 
and docosahexaenoic acid-supplemented group. 
 
Figure 3. (a) Mean lung bacterial load, (b) free alveolar space (%), and representative hematoxylin-
eosin staining of lungs for (c) control, (d) EPA/DHA, (e) Fe, (f) Fe+EPA/DHA groups after providing 
Mtb-infected mice with control, EPA/DHA, Fe, or Fe+EPA/DHA diets for three weeks. The values 
represent mean ± SEM. Results repeated in two experiments, data shown for one experiment (n = 5 
per group). Two-way ANOVA was used to test effects of EPA/DHA (control & Fe vs. EPA/DHA & 
Fe+EPA/DHA), Fe (control & EPA/DHA vs. Fe & Fe+EPA/DHA), and Fe × EPA/DHA interactions. 
One-way ANOVA followed by Tukey post-hoc test was used to compare means. * p < 0.05. CFU: 
colony-forming units; EPA/DHA: eicosapentaenoic and docosahexaenoic acid-supplemented group; 
Fe: iron-supplemented group; Fe+EPA/DHA: iron plus eicosapentaenoic and docosahexaenoic acid-
supplemented group. 
3.5. Lipid Mediators in Crude Lung Homogenates 
Next, we measured lung LM concentrations, as this was the target site of our intervention and 
we hypothesized that LM production would be altered according to the FA composition of the 
intervention diets. As shown in Figure 4, EPA/DHA supplementation of Mtb-infected mice resulted 
in higher lung concentrations of the EPA-derived PGE3 (p < 0.001) and pro-resolving LM 
intermediates 5- (p = 0.047), 11- (p < 0.001), 12- (p = 0.002), 15- (p < 0.001), and 18-HEPE (p < 0.001), as 
well as DHA-derived 17-HDHA (p = 0.023) (Figure 4a–f). There was an antagonistic Fe × EPA/DHA 
interaction for the AA-derived pro-inflammatory intermediate 11-HETE (p = 0.047) and a tendency 
towards an antagonistic interaction for 15-HETE (p = 0.08), but there were no significant differences 
between groups (Supplemental Figure S1a,b). No treatment effects could be found on the other pro-
inflammatory LMs that were measured. 
Figure 3. (a) Mean lung bacterial load, (b) free alveolar space (%), and representative hematoxylin-eosin
staining of lungs for (c) contr l, (d) EPA/DHA, (e) Fe, (f) Fe+EPA/DHA groups i i g
tb-i f t i i / , , r Fe e l es
represe t e t 5
per grou ). ff . EP /
Fe / . EP / ), and e EP / A interactions.
ne- fol o ukey post-hoc test as use to co pare ea s. . CFU:
colo -f r i / : i ic ci -s pple ented group;
Fe: iron-supplemented group; Fe+EPA/DHA: iron plus eicosap taenoic and docosahexaenoic
acid-supplemented group.
3.5. Lipid Mediators in Crude Lung Homogenates
Next, we measured lung LM concentrations, as this was the target site of our intervention
and we hypothesized that LM production would be altered according to the FA composition of the
intervention diets. As shown in Figure 4, EPA/DHA supplementation of Mtb-infected mice resulted in
higher lung concentrations of the EPA-derived PGE3 (p < 0.001) and pro-resolving LM intermediates
5- (p = 0.047), 11- (p < 0.001), 12- (p = 0.002), 15- (p < 0.001), and 18-HEPE (p < 0.001), as well as
DHA-derived 17-HDHA (p = 0.023) (Figure 4a–f). There was an antagonistic Fe × EPA/DHA interaction
for the AA-derived pro-inflammatory intermediate 11-HETE (p = 0.047) and a tendency towards an
antagonistic interaction for 15-HETE (p = 0.08), but there were no significant differences between groups
(Supplemental Figure S1a,b). No treatment effects could be found on the other pro-inflammatory LMs
that were measured.
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(e) 18-HEPE and (f) 17-HDHA after providing tb-infected mice with control, EPA/DHA, Fe, or
Fe+EPA/DHA diets for three weeks. Results repeated in two experiments, data shown for one
experiment (n = 5 per group). Two-way ANOVA was used to test effects of EPA/DHA (control
& Fe vs. EPA/DHA & Fe+EPA/DHA), Fe (control & EPA/DHA vs. Fe & Fe+EPA/DHA), and
Fe × EPA/DHA interactions. One-way ANOVA followed by Tukey post-hoc test was used to compare
groups. * p < 0.05, ** p < 0.01, *** p < 0.001. EPA/DHA: eicosapentaenoic and docosahexaenoic
acid-supplemented group; Fe: iron-supplemented group; Fe+EPA/DHA: iron plus eicosapentaenoic
and docosahexaenoic aci -supplemented group; HDHA: hydroxy-docosahexaenoic acid; HEPE:
hydroxy-eicosapentaenoic acid.
3.6. Other Markers of the Immune and Inflammatory Response
Lung and plasma cytokines were measured to determine local and systemic inflammatory effects,
respectively (Figures 5 and 6). We observed antagonistic Fe × EPA/DHA interactions for lung IL-1α
(p = 0.001), lL-1β (p = 0.003) and IFN-γ (p = 0.016) (Figure 5a–c). The Mtb-infected mice supplemented
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with EPA/DHA or Fe alone had significantly lower lung IL-1α concentrations than the control mice
(p = 0.039 and p = 0.049), but the IL-1α-lowering effects were attenuated in mice supplemented with
Fe+EPA/DHA (Figure 5a). The mice supplemented with Fe had lower lung lL-1β compared with
control mice (p = 0.022), but not the mice supplemented with Fe+EPA/DHA (Figure 5b). Compared
with the control groups, EPA/DHA supplementation significantly lowered lung IFN-γ concentrations
only in the mice receiving EPA/DHA alone (p = 0.003), but not in the mice receiving EPA/DHA in
combination with iron (Figure 5c). Furthermore, there was a main effect of EPA/DHA supplementation
for higher lung CCL3 concentrations (p = 0.004), but only the mice receiving EPA/DHA alone had
significantly higher CCL3 compared with the control mice (p = 0.026) (Figure 5d).Nutrients 2020, 12, x FOR PEER REVIEW 13 of 22 
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Concerning plasma cytokines (Figure 6), we observed Fe × EPA/DHA interactions for the
inflammatory plasma cytokines IL-1α, IL-1β, and TNF-α (p = 0.044, p = 0.029, and p = 0.014) (Figure 6a–c).
EPA/DHA and iron supplementation significantly and equally lowered plasma IL-1β when provided
alone or in combination (p = 0.030, p = 0.007, and p = 0.029) (Figure 6b). A similar pattern was observed
for IL-1α, TNF-α, and IL-6. There were no significant main effects or between-group differences for
plasma IL-1α (Figure 6a). TNF-α was significantly lower in the mice supplemented with EPA/DHA
(p = 0.040) and Fe (p = 0.009) when compared with the control mice, but only tended to be lower in the
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Fe+DHA/EPA group (p = 0.060) (Figure 6c). There were also main effects of EPA/DHA and Fe for lower
plasma IL-6 concentrations (p = 0.022 and p = 0.011), resulting in significantly lower plasma IL-6 in the
Fe and Fe+EPA/DHA groups compared with the control mice (p = 0.038 and p = 0.006, Figure 6d).Nutrients 2020, 12, x FOR PEER REVIEW 14 of 22 
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rep ated in two experiments, data sho n f i ent (n = 5 per group). Two-way ANOVA
was used to test effects of EPA/DHA (control & Fe s. / A & Fe+EPA/DHA), Fe (control &
EPA/DHA vs. Fe & Fe+EPA/DHA), and Fe × EP / interactions. One-way ANOVA followed by
Tukey post-hoc test was used to compare means. * p < 0.05, ** p < 0.01. EPA/DHA: eicosapentaenoic
and docosahexaenoic acid-supplemented group; Fe: iron-supplemented group; Fe+EPA/DHA: iron
plus eicosapentaenoic and docosahexaenoic acid-supplemented group; IL: interleukin; TNF-α: tumor
necrosis factor-alpha.
We also compared the lung immune cell phenotypes determined by flow cytometry and showed
absolute counts (Figure 7) and percentages of total cells (Supplemental Figure S2) in a single cell
suspension of the lungs. We found main effects of iron supplementation for higher counts of T cells
(p = 0.011), CD4+ T cells (p = 0.001), CD8+ T cells (p = 0.007), interstitial macrophages (p = 0.004),
alveolar macrophages (p = 0.035), CD103 dendritic cells (DCs) (p = 0.035), and CD11b DCs (p = 0.001)
(Figure 7a–e, data not shown for interstitial macrophages), as well as percentage of total cells in
neutrophils (p = 0.022), monocyte-derived DCs (mo DCs) (p = 0.002), natural killer (NK) cells
(p = 0.006), T cells (p = 0.001), CD4+ T cells (p < 0.001), CD8+ T cells (p = 0.003), interstitial macrophages
(p = 0.003), and CD11b DCs (p < 0.001) (Supplemental Figure S2a–f,h) in Mtb-infected mice. On the
other hand, there were main effects or trends of EPA/DHA supplementation for lower T cell counts
(p = 0.07), as well as T cells (p = 0.045), and CD4+ T cells (p = 0.07) as percentages of total cells.
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Furthermore, we found attenuating Fe × EPA/DHA interactions on CD8+ T cell counts (p = 0.050) and
CD11b DC counts (p = 0.018) (Figure 7c,f). For both cell types, supplementation of iron alone resulted
in significantly higher cell counts compared to control mice (p = 0.001 and p = 0.010), but this increase
was attenuated in the Fe+EPA/DHA mice (Fe+EPA/DHA vs. control, p = 0.19 and p = 0.98).Nutrients 2020, 12, x FOR PEER REVIEW 15 of 22 
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Figure 7. Lung i une cell counts after providing tb-infected ice ith control, EP / , Fe, or
Fe+EP / diets for three eeks, including (a) T cells, (b) CD4+ T cells, (c) C 8+ T cells, (d) alveolar
acrophages, (e) CD103 DCs, and (f) CD11b DCs. The values represent ean ± SE . Results repeated
in two experiments, data shown for one experiment (n = 5 per group). Two-way ANOVA was used to
test effects of EPA/DHA (control & Fe vs. EPA/DHA & Fe+EPA/DHA), Fe (control & EPA/DHA vs. Fe
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and docosahexaenoic acid-supplemented group; Fe: iron-supplemented group; Fe+EPA/DHA: iron
plus eicosapentaenoic and docosahexaenoic acid-supplemented group; macs: macrophages.
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4. Discussion
This study provides evidence, for the first time to our knowledge, that both EPA/DHA and
iron independently administered to Mtb-infected mice, lowers inflammation and improves indices
of anemia of infection. Additionally, EPA/DHA lowered bacterial load, which may be related to the
enhanced phagocytic ability of immune cells [22,23] and increased synthesis of EPA and DHA-derived
LMs. Interestingly, iron neither improved nor reduced bactericidal effects, but when combined with
EPA/DHA supplementation, the bactericidal effect of EPA/DHA was attenuated. The main findings of
this research are summarized in Figure 8.Nutrients 2020, 12, x FOR PEER REVIEW 18 of 22 
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Figure 8. Summary of the findings of this research. DHA: docosahexaenoic acid; EPA: eicosapentaenoic
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When compared with the uninfected reference group, it was clear that the infected control mice
presented with a typical profile of anemia of infection showing elevated sTfR, ferritin, and hepcidin but
reduced liver iron levels [18]. Higher sTfR concentrations have been reported in inflammatory situations
and in TB specifically, owing to the higher iron demand and erythropoietic stimulus resulting from
inflammation-induced hypoferremia [2,18,31]. This occurrence is underpinned by the higher levels of
circulating hepcidin that we found, which functions to reduce iron absorption and iron exportation
from cells into plasma [18,32]. In essence, there is an intracellular shift of iron as part of the host
defense to reduce iron availability for extracellular pathogens, which require iron for growth [14,33,34].
However, both EPA/DHA and iron supplementation alone lowered hepcidin levels. This may be
explained by the fact that high circulating hepcidin is mainly stimulated by IL-6, but also IL-1 [32,35–37].
Both EPA/DHA and iron supplementation alone had a lowering effect on IL-1β and IL-6. Hepcidin
is also regulated by the infection itself and has known antimicrobial properties [32,38,39]. Therefore,
the finding that mice supplemented with EPA/DHA alone also had a lower bacterial burden further
explains the lower hepcidin concentrations observed in this group. Additionally, sTfR concentrations
increase during tissue iron deficiency but are lower where there is iron abundance, also explaining
the results in the Fe group [40]. Our findings that ferritin concentrations were lower in the Fe group
and tended to be lower in the EPA/DHA group compared with the control group support that ferritin
instead acts as an acute-phase protein and not as a marker of stored iron in TB [6,16,41]. However, we
found antagonistic interactions of iron and EPA/DHA on ferritin, TfR and hepcidin concentrations, as
the lowering effect of supplementing iron or EPA/DHA individually was attenuated in mice receiving
the combination treatment. Additionally, liver iron concentrations were lower in the control group
when compared with the healthy reference groups, but not in the supplemented groups. Our results
suggest that the provision of iron or EPA/DHA alone has similar effects of reducing inflammation
and thereby improving biomarkers indicative of anemia of infection but that Fe+EPA/DHA treatment
did not. Moreover, iron supplementation effectively improved iron status during infection as evident
from the higher liver iron concentrations. However, Hb concentrations did not react similarly. The Hb
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concentrations of the infected groups were not found to be significantly different from the uninfected
reference group. This was likely related to the short duration of the infection period. The erythrocyte
life span in mice is ~ 40 days, which may explain why Hb concentrations remained more stable
compared to other markers and may also be related to Hb’s essential biological functions [42].
Improvements in inflammation mediated the improvements in the biomarkers of iron status and
anemia of infection in the EPA/DHA and Fe groups. Mutually, TNF-α, IFN-γ, and IL-1 are important
in host defense against TB, but higher concentrations of these markers have also been associated
with worsened lung pathology together with disease severity [43–45]. We found that EPA/DHA
therapy lowered the pro-inflammatory plasma cytokines IL-1β and TNF-α as well as lung IL-1α
and IFN-γ. This is in congruence with the lower bacterial load [45] and a more pro-resolving lung
LM profile found in the EPA/DHA group, resulting from changes in the FA composition evident
in all FA pools measured. In contrast to these findings, iron supplementation resulted in a higher
n-6 LCPUFA composition of PBMCs and lung tissue membranes. This finding opposes previous
research indicating that higher iron intakes favor higher n-3 LCPUFA membrane composition by
affecting desaturase activities and/or membrane incorporation [46,47]. The reason for the discrepancies
may be that these studies were conducted in healthy humans and not under infectious conditions,
whereby membrane LCPUFAs may become depleted due to increased LM production during infections.
Nevertheless, these FA composition changes did not influence the LM profile or cytokines in the Fe
group, which presented with lower plasma IL-1β, IL-6 and TNF-α, as well as lung IL-1α and IL-1β
concentrations compared with the control group. Our results agree with gene-expression studies,
which found that the expression of IL-1α, IL-1β, and TNF-αwas downregulated in macrophages, blood
and livers of TB infected rabbits and mice that were supplemented with iron [48–50]. Similar to the
EPA/DHA group, a pro-resolving LM profile was found in the Fe+EPA/DHA group, together with
lower pro-inflammatory plasma cytokines. Our group had previously also established that when
providing iron with EPA/DHA in iron-deficient school children, the pro-resolving LM profile produced
by EPA and DHA was maintained [25].
We further investigated the effects of our intervention diets on lung immune cell phenotypes.
We found that EPA/DHA lowered T cell recruitment, likely by decreasing T cell proliferation that is
induced by EPA and DHA, together with the lower bacterial burden that was found in the EPA/DHA
group [51–53]. This is supported by previous research on n-3 PUFA supplementation in TB [51]. In
contrast, dietary iron supplementation led to higher counts and percentages of various immune cells
in the lungs. Iron has previously been shown to affect T cell numbers, whereby iron deficiency reduces
the proliferation of T cells [54,55]. The Fe group presented with higher counts of total T cells, CD4+ T
cells, and CD8+ T cells. This finding is consistent with previous research, where higher CD8+ T cell
recruitment was reported in the granulomas of M. bovis BCG-infected mice that received iron-rich
diets [48]. When provided in combination with EPA/DHA, these effects of iron were attenuated, which
was probably related to the effects of EPA/DHA described above. Furthermore, phagocytic cells are
produced at infection sites to compete with the Mtb for iron acquisition [56,57]. This partly explains the
higher macrophages, monocytes, and DCs that were evident in the lungs of mice in the Fe group, which
is consistent with the findings of others [58]. However, again when supplemented with EPA/DHA, this
effect of iron was attenuated. Even though there were alterations in lung inflammation and immune
cell phenotypes amongst the different intervention groups, there were no main treatment effects of
EPA/DHA or iron on lung pathology, which is consistent with the findings of others [48,51]. Conversely,
it seemed that combination treatment again did not deliver favorable clinical outcomes, which elicited
a trend to reduce free alveolar space, and therefore worsen lung pathology.
Iron supplementation did not affect bacterial load in our study. These findings, although
unexpected, because iron is crucial for Mtb growth and virulence [34], are consistent with previous
research in Mtb-infected animals and humans [1,48,49,59,60]. Our findings and those of previous
research are partly explained by the fact that Mtb is an intracellular bacterium able to obtain iron,
irrespective of the host iron regulatory mechanisms and iron status [1,60]. Furthermore, iron has
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important functions in the antibacterial activity of macrophages and T cells, and serves as co-factor
for various enzymes [14,61]. This suggests its importance in host resistance, rather than promoting
bacterial growth. Contrasting with our findings, others have suggested that iron abundance enhanced
Mtb growth in mice [62–64], which may be related to the use of genetically modified mice [64]
or intraperitoneally administered iron, resulting in high circulatory iron concentrations [62,63].
A recent review by Agoro and Mura [14] suggested an “iron benefit window” where moderate
iron supplementation may enhance the immune response to lower inflammation and bacterial
burden. However, beyond this threshold, iron instead augments inflammation and bacterial load [14].
Interestingly, in our study, iron lowered body weight gain in C3HeB/FeJ mice. This is in contrast with
previous studies, showing no effect of iron on body weight changes in Mtb-infected BALB/C mice and
humans and is not explained by the inflammatory profile or bacterial burden in the iron-supplemented
group [1,63].
This study is strengthened by the use of a well-established TB rodent (C3HeB/FeJ) model that
closely reflects human pulmonary TB pathology [65]. This is also the first study, to our knowledge, to
compare iron supplementation directly with an inflammation-resolving therapy in TB. This study is
limited by the fact that we measured outcomes at only one time point in the inflammatory response.
Furthermore, based on its outcomes, investigating the effect of EPA/DHA as host-directed therapy
adjunct to standard TB treatment in an equivalent mouse model is needed before a clinical trial can
be recommended.
5. Conclusions
The findings of this study indicate that EPA/DHA or iron supplementation alone exerted similar
benefits concerning systemic and lung inflammation and markers of anemia of infection in TB in the
absence of standard TB drugs. Additionally, EPA/DHA supplementation induced a more pro-resolving
lung LM profile that was maintained with combination treatment. It also enhanced bactericidal activity
without influencing lung immune cell recruitment or body weight gain, as was the case with iron
supplementation. However, the combination of Fe+EPA/DHA treatment did not exert the beneficial
effects observed with EPA/DHA or iron supplementation alone on clinical outcomes, markers of
anemia of infection, or lung inflammation. Therefore, EPA/DHA supplementation after infection
may be a strategy to consider in supporting the resolution of inflammation and mitigation of anemia
of infection without compromising host immunity in TB. Additionally, contrary to current belief,
iron supplementation may have a modest effect on lowering inflammation without influencing lung
bacterial burden. Iron supplementation may, therefore, be an effective option to improve iron status
safely during TB infection, which warrants further investigation.
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